Printer Friendly

Response to: Comment on "Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema".

We would like to thank G. Sikri and S. Bhattachar for their insightful comment [1] on our article suggesting a role of low-grade cellular-based inflammation as indicated by elevated soluble urokinase-type plasminogen activator receptor (suPAR) plasma concentrationon in the pathogenesis of high altitude pulmonary edema (HAPE) [2].

The adaptation of the cardiovascular system to hypobaric hypoxia is an important entity in all high altitude studies. Recent data from a study using pharmacological blockade of the sympathetic and parasympathetic nervous system [3] suggest that even though sympathetic nervous system activity increases as compared to normoxic state, parasympathetic withdrawal rather than sympathetic activation seems to be the cause of the increase in heart rate observed in healthy humans subjected to hyperbaric hypoxia. Even though the effect of dexamethasone on the autonomic nervous system is not fully understood, dexamethasone administration has previously been shown to decrease heart rate during hypoxic exposure [4]. It is thus in concordance with current literature that dexamethasone intake is the likely cause of the different course of HR during hypoxic exposure seen in our study population ([DELTA]HR +16/min versus -7/min, p <0.01, in the no prophylaxis (n = 31) versus the dexamethasone prophylaxis (n = 10) group).

As G. Sikri and S. Bhattachar point out, it is empirically known that HAPE incidence at altitude can only be assessed after several days of high altitude exposure. We agree, epidemiological studies have clearly shown that HAPE is a hydrostatic type of pulmonary edema which develops within the first days but no later than five days of exposure to high altitude. In the setting of the Margherita studies, we observed that up to 70% of the HAPE susceptible mountaineers develop HAPE within 72 hours of arrival [5, 6]. Results of a recent study of hemodynamic adaptation to a constant altitude of 3454 m over three weeks further suggest the occurrence of early pulmonary vascular remodeling within less than 21 days as an underlying mechanism for a subsequent decrease in HAPE incidence [7]. Our study was designed to answer the question whether low-grade cellular-based inflammation as indicated by elevated suPAR plasma concentration could predict HAPE susceptibility. Even though our data indicates such a connection, the question if suPAR plasma concentration also correlates with HAPE incidence at altitude remains unanswered. As described in our study, after the first 24 hours at altitude, subjects that have not received dexamethasone prophylaxis before ascent were randomized into a group that received post exposure ("late") prophylaxis of 8 mg oral dexamethasonebidaily (n = 20) and a control group that did not receive dexamethasone (n = 11). Thus, HAPE incidence at high altitude depended on dexamethasone administration, and the groups are not large enough for a subgroup analysis regarding baseline suPAR plasma concentration. It is however of interest that dexamethasone application at high altitude partly reversed the hypoxia-associated increase in suPAR and interleukin-6 (IL-6) plasma concentration within 48 hours, while this was not the case for c-reactive protein (CRP; see Table 1).

https://doi.org/10.1155/2018/8036759

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] G. Sikri and S. Bhattachar, "Comment on "soluble urokinase-type plasminogen activator receptor plasma concentration may predict susceptibility to high altitude pulmonary edema"," Mediators of Inflammation, vol. 2017, Article ID 8546027, 2 pages, 2017.

[2] M. P. Hilty, S. Zugel, M. Schoeb, K. Auinger, C. Dehnert, and M. Maggiorini, "Soluble urokinase-type plasminogen activator receptor plasma concentration may predict susceptibility to high altitude pulmonary edema," Mediators of Inflammation, vol. 2016, Article ID 1942460, 8 pages, 2016.

[3] C. Siebenmann, P. Rasmussen, M. Hug et al., "Parasympathetic withdrawal increases heart rate after 2 weeks at 3454 m altitude," The Journal of Physiology, vol. 595, no. 5, pp. 1619-1626, 2017.

[4] M. Maggiorini, H.-P. Brunner-La Rocca, S. Peth et al., "Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial," Annals of Internal Medicine, vol. 145, no. 7, pp. 497-506, 2006.

[5] E. R. Swenson, M. Maggiorini, S. Mongovin et al., "Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor," JAMA, vol. 287, no. 17, pp. 2228-2235, 2002.

[6] M. Maggiorini, C. Melot, S. Pierre et al., "High-altitude pulmonary edema is initially caused by an increase in capillary pressure," Circulation, vol. 103, no. 16, pp. 2078-2083, 2001.

[7] M. P. Hilty, A. Muller, D. Fluck et al., "Effect of increased blood flow on pulmonary circulation before and during high altitude acclimatization," High Altitude Medicine & Biology, vol. 17, no. 4, pp. 305-314, 2016.

Matthias Peter Hilty [ID], (1) Stefanie Zuge (l,2) Michele Schoeb, (1) Katja Auinger, (1) Christoph Dehnert, (2) and Marco Maggiorini [ID], (1)

(1) Medical Intensive Care Unit, University Hospital of Zurich, Zurich, Switzerland

(2) Institute for Sports Medicine, Rupert-Karls University of Heidelberg, Heidelberg, Germany

Correspondence should be addressed to Matthias Peter Hilty; matthias.hilty@usz.ch

Received 15 December 2017; Accepted 28 March 2018; Published 2 May 2018

Academic Editor: Michal A. Rahat
Table 1: Development of suPAR, CRP, and IL-6 plasma
concentration during 48 hours of exposure to 4559 m.

                            High altitude,    High altitude,
                               24 hours          72 hours
suPAR [ng/ml]

Entire sample (n = 31)        2.27 (2.20)       2.08 (2.00)
No steroids (n = 11)          2.13 (2.00)       2.03 (1.90)
Therapy (n = 20)              2.33 (2.25)       2.11 (2.05)

CRP [mg/l]

Entire sample (n = 31)        3.57 (2.20)       3.43 (2.60)
No steroids (n = 11)          1.81 (1.60)       2.76 (2.60)
Therapy (n = 20)              4.45 (2.50)       3.76 (2.50)

IL-6 [ng/l]

Entire sample (n = 31)        2.71 (2.05)       1.51 (0.73)
No steroids (n = 11)          2.45 (2.05)       2.67 (1.75)
Therapy (n = 20)              2.91 (2.21)       0.64 (0.34)

                            p value, delta median (95% CI)

suPAR [ng/ml]

Entire sample (n = 31)       p = 0.34, A0.10 (-0.05-0.20)
No steroids (n = 11)        p = 0.34, A-0.15 (-0.35-0.10)
Therapy (n = 20)             p = 0.04, A0.20 (0.00-0.30)

CRP [mg/l]

Entire sample (n = 31)       p = 0.77, A0.10 (-0.75-1.40)
No steroids (n = 11)        p = 0.08, A-1.13 (-2.70-0.05)
Therapy (n = 20)             p = 0.18, A1.25 (-0.30-2.40)

IL-6 [ng/l]

Entire sample (n = 31)       p = 0.01, A 1.04 (0.23-2.60)
No steroids (n = 11)         p = 0.58, A0.33 (-3.19-1.25)
Therapy (n = 20)             p = 0.01, A2.18 (0.69-4.06)

Comparison of inflammatory marker plasma concentration at 24 versus
72 hours was performed using related sample Wilcoxon signed rank
test. Values are given as median (IQR). Delta median corresponds to
the median of the difference between samples from both timepoints.
suPAR: soluble urokinase-type plasminogen activator receptor; IL-6:
interleukin-6; CRP: c-reactive protein; CI: confidence interval.
COPYRIGHT 2018 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Letter to the Editor
Author:Hilty, Matthias Peter; Zugel, Stefanie; Schoeb, Michele; Auinger, Katja; Dehner, Christoph; Maggiori
Publication:Mediators of Inflammation
Date:Jan 1, 2018
Words:1141
Previous Article:Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
Next Article:Emerging Roles of Immune Cells in Postoperative Cognitive Dysfunction.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |